These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 28079787)
1. Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report. Schmouchkovitch A; Herry H; Thuillier P; Kerlan V; Fleuret C; Le Toux G; Boisramé S Medicine (Baltimore); 2017 Jan; 96(2):e5075. PubMed ID: 28079787 [TBL] [Abstract][Full Text] [Related]
2. Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report. Jebabli N; Gaïes E; Eljebari H; Charfi R; Lakhal M; Klouz A; Salouage I; Trabelsi S Therapie; 2015; 70(6):545-6. PubMed ID: 26242497 [TBL] [Abstract][Full Text] [Related]
3. Mitotane-induced dyspnoea: an unusual side effect. Farooq AU; Amjad W; Kochar T; Adhikari S BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30173131 [TBL] [Abstract][Full Text] [Related]
4. [Mitotane in the treatment of adrenal carcinoma]. Sane T Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521 [TBL] [Abstract][Full Text] [Related]
5. [Mitotane as possible cause of acute intermittent porphyria]. von Eyben FE Ugeskr Laeger; 2011 Sep; 173(37):2268-9. PubMed ID: 21917227 [TBL] [Abstract][Full Text] [Related]
7. Oral lichenoid drug reaction associated with antihypertensive and hypoglycemic drugs. Kaomongkolgit R J Drugs Dermatol; 2010 Jan; 9(1):73-5. PubMed ID: 20120430 [TBL] [Abstract][Full Text] [Related]
8. Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: Clinical and experimental observations. Abrahamsson G; Ekerhovd E; Janson PO; Jansson S; Ahlman H; Wängberg B; Norström A Acta Obstet Gynecol Scand; 2020 Oct; 99(10):1297-1302. PubMed ID: 32282928 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients. Maiter D; Bex M; Vroonen L; T'Sjoen G; Gil T; Banh C; Chadarevian R Ann Endocrinol (Paris); 2016 Oct; 77(5):578-585. PubMed ID: 27063476 [TBL] [Abstract][Full Text] [Related]
11. Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma. De León DD; Lange BJ; Walterhouse D; Moshang T J Clin Endocrinol Metab; 2002 Oct; 87(10):4452-6. PubMed ID: 12364417 [TBL] [Abstract][Full Text] [Related]
12. [Practical use of o,p'DDD in adrenocortical carcinoma]. Bacchetta J; Droz JP Bull Cancer; 2005 Mar; 92(3):273-9. PubMed ID: 15820922 [TBL] [Abstract][Full Text] [Related]
13. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Mauclère-Denost S; Leboulleux S; Borget I; Paci A; Young J; Al Ghuzlan A; Deandreis D; Drouard L; Tabarin A; Chanson P; Schlumberger M; Baudin E Eur J Endocrinol; 2012 Feb; 166(2):261-8. PubMed ID: 22048971 [TBL] [Abstract][Full Text] [Related]
14. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287 [TBL] [Abstract][Full Text] [Related]
15. Mitotane treatment for adrenocortical carcinoma: an overview. De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612 [TBL] [Abstract][Full Text] [Related]
16. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714 [TBL] [Abstract][Full Text] [Related]
17. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. Terzolo M; Pia A; Berruti A; Osella G; Alì A; Carbone V; Testa E; Dogliotti L; Angeli A J Clin Endocrinol Metab; 2000 Jun; 85(6):2234-8. PubMed ID: 10852456 [TBL] [Abstract][Full Text] [Related]